Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients. For this trial, one unique vaccine is designed and manufactured for each patient.
Vaccibody has a collaboration with Nektar Therapeutics and is planning to start testing VB10.NEO in combination with bempegaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck.